Research
Hormonal
GLP-1 receptor agonists and DPP-4 inhibitors both have a low risk of hypoglycemia when used as monotherapy due to their glucose-dependent mechanism of action.
Both GLP-1 injections and DPP-4 inhibitor pills are safe in terms of hypoglycemia risk when taken alone. They only work to lower blood sugar when it is elevated, unlike insulin or sulphonylureas which can cause dangerous lows if you skip a meal.
StrongSupportsVERY_HIGH confidence
Both agents produce reductions in plasma glucose and, as a result of their glucose-dependent mode of action, this is associated with low rates of hypoglycaemia
Why this rating
Consistently stated across the paper for both drug classes.
Source
Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors
Michael A. Nauck · Diabetes Obesity and Metabolism · 2015
DOI 10.1111/dom.12591
narrative_reviewCited 426×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) provide superior glycemic control compared to DPP-4 inhibitors in type 2 diabetes, primarily due to higher pharmacological concentrations of GLP-1 and distinct tissue distribution patterns.Good
- GLP-1 receptor agonists promote weight loss, whereas DPP-4 inhibitors are generally weight-neutral, making GLP-1RAs more suitable for obese T2D patients.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →